| GlaxoSmithKline AG - Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung |
| 65731 | | 01 | | Nucala 100 mg | | Lyophilisat zur Herstellung einer Injektionslösung | | R03DX09 | | Mepolizumab | | 07.04.2016 | | |
|
| Composition |
| Praeparatio cryodesiccata: mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus corresp. natrium 1.5-2 mg, polysorbatum 80, acidum hydrochloricum q.s. ad pH pro vitro. |
| Packungsbestandteile |
| Praeparatio cryodesiccata: | | | Lyophilisate | | | | | | | | Active Agent | Dose |
|---|
| Mepolizumabum | 100 mg |
| | BAG: Active Agent | Dose |
|---|
| Mepolizumabum | 100 mg |
| | | | Inactive agents |
|---|
| Hydrochloric Acid | | Disodium Phosphate Heptahydrate | | Polysorbatum 80 | | Saccharum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 976.63 | 1078.55 | B | SL | Yes |
|
